MA42266A - Agent thérapeutique contre la fibrose - Google Patents

Agent thérapeutique contre la fibrose

Info

Publication number: MA42266A
Authority: MA; Morocco
Prior art keywords: therapeutic agent; agent against; against fibrosis; fibrosis; therapeutic
Prior art date: 2015-06-25

Application number

MA042266A

Other languages

English (en)

Inventor

Akio Fujioka

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-25

Filing date

2016-06-24

Publication date

2018-05-02

2016-06-24 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2018-05-02 Publication of MA42266A publication Critical patent/MA42266A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)

MA042266A 2015-06-25 2016-06-24 Agent thérapeutique contre la fibrose MA42266A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2015127788		2015-06-25

Publications (1)

Publication Number	Publication Date
MA42266A true MA42266A (fr)	2018-05-02

Family

ID=57585165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA042266A MA42266A (fr)	2015-06-25	2016-06-24	Agent thérapeutique contre la fibrose

Country Status (20)

Country	Link
US (4)	US10449189B2 (fr)
EP (2)	EP3973962A1 (fr)
JP (3)	JP6974167B2 (fr)
KR (1)	KR102647942B1 (fr)
CN (2)	CN112716952A (fr)
AU (1)	AU2016284531B2 (fr)
BR (1)	BR112017028137B1 (fr)
CA (1)	CA2990791A1 (fr)
DK (1)	DK3315131T3 (fr)
ES (1)	ES2928684T3 (fr)
HU (1)	HUE060732T2 (fr)
MA (1)	MA42266A (fr)
MX (2)	MX381792B (fr)
MY (1)	MY191219A (fr)
PH (1)	PH12017502322B1 (fr)
PL (1)	PL3315131T3 (fr)
PT (1)	PT3315131T (fr)
RU (1)	RU2729630C2 (fr)
SG (2)	SG11201709260TA (fr)
WO (1)	WO2016208744A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8324454B2 (en)	2006-03-14	2012-12-04	Ceres, Inc.	Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en)	2006-03-14	2024-11-26	Ceres, Inc.	Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
EP3583943B1 (fr)	2017-02-15	2024-09-18	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique
JP7074760B2 (ja)	2017-09-08	2022-05-24	大鵬薬品工業株式会社	抗腫瘍剤及び抗腫瘍効果増強剤
US20210369739A1 (en)	2018-09-18	2021-12-02	Taiho Pharmaceutical Co., Ltd.	Combination therapy of acylthiourea compound and abiraterone
TWI872203B (zh) *	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
CN115177636A (zh) *	2022-07-18	2022-10-14	陕西科美致尚生物科技有限公司	一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2327382C (fr)	1998-04-28	2012-12-18	Toshikazu Nakamura	Inhibiteurs de neovascularisation
JP2003238592A (ja) *	2001-12-13	2003-08-27	Japan Tobacco Inc	組織及び血管の再生のための医薬及びその方法
AU2006265835B2 (en)	2005-06-30	2012-05-03	Amgen Inc.	Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
ZA200804681B (en) *	2005-11-30	2009-11-25	Vertex Pharma Inc	Inhibitors of C-Met and uses thereof
JP5144532B2 (ja)	2005-11-30	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	ｃ−Ｍｅｔ阻害剤及び用法
AU2008219166B2 (en)	2007-02-16	2013-05-16	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
AU2008315746A1 (en)	2007-10-25	2009-04-30	Astrazeneca Ab	Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
DK2287155T3 (da)	2008-04-10	2013-07-29	Taiho Pharmaceutical Co Ltd	Acylthiourea-forbindelse eller salt deraf samt anvendelse deraf
UY32049A (es) *	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
EA025304B1 (ru)	2010-02-03	2016-12-30	Инсайт Холдингс Корпорейшн	ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
ES2715611T3 (es)	2010-05-17	2019-06-05	Incozen Therapeutics Pvt Ltd	Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
TWI594986B (zh)	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
RU2494470C1 (ru) *	2012-04-04	2013-09-27	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент")	Способ лечения фиброза легких
US9149471B2 (en)	2013-09-30	2015-10-06	National University Corporation Tokyo University Of Agriculture And Technology	Therapeutic agent for osteoporosis

2016
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/fr not_active Withdrawn
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/fr not_active Ceased
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/fr active Pending
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/fr active Active
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active

Also Published As

Publication number	Publication date
CN112716952A (zh)	2021-04-30
RU2017145271A3 (fr)	2019-12-02
CN107708697B (zh)	2021-02-09
RU2729630C2 (ru)	2020-08-11
HK1245639A1 (zh)	2018-08-31
US10695340B2 (en)	2020-06-30
US20220047572A1 (en)	2022-02-17
HUE060732T2 (hu)	2023-04-28
EP3315131B1 (fr)	2022-09-14
MX381792B (es)	2025-03-13
BR112017028137A2 (pt)	2018-08-28
US11690838B2 (en)	2023-07-04
CN107708697A (zh)	2018-02-16
JP7498827B2 (ja)	2024-06-12
SG10201912684TA (en)	2020-03-30
US20180289690A1 (en)	2018-10-11
JP2022009994A (ja)	2022-01-14
PH12017502322B1 (en)	2023-08-30
PL3315131T3 (pl)	2022-12-12
KR20180021682A (ko)	2018-03-05
JP6974167B2 (ja)	2021-12-01
PH12017502322A1 (en)	2018-06-25
KR102647942B1 (ko)	2024-03-14
MX2020012989A (es)	2021-02-16
ES2928684T3 (es)	2022-11-21
DK3315131T3 (da)	2022-11-14
JP7258985B2 (ja)	2023-04-17
US10449189B2 (en)	2019-10-22
PT3315131T (pt)	2022-10-26
US11191759B2 (en)	2021-12-07
JP2023076632A (ja)	2023-06-01
WO2016208744A1 (fr)	2016-12-29
MX2017016774A (es)	2018-05-14
CA2990791A1 (fr)	2016-12-29
JPWO2016208744A1 (ja)	2018-04-12
EP3315131A4 (fr)	2019-02-27
MY191219A (en)	2022-06-09
US20200009128A1 (en)	2020-01-09
AU2016284531B2 (en)	2020-06-04
US20200297716A1 (en)	2020-09-24
EP3973962A1 (fr)	2022-03-30
SG11201709260TA (en)	2018-01-30
BR112017028137B1 (pt)	2023-04-04
RU2017145271A (ru)	2019-07-25
EP3315131A1 (fr)	2018-05-02
AU2016284531A1 (en)	2017-11-30

Publication	Publication Date	Title
FIC20240025I1 (fi)	2024-07-12	Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
HRP20181692T1 (hr)	2018-12-14	Liječenje fibroze
IL250685A0 (en)	2017-04-30	Medicinal substance induces cytotoxicity
EP3314027A4 (fr)	2019-07-03	Oligonucléotides thérapeutiques
SG10201912416QA (en)	2020-02-27	Therapeutic agents
BR112016021682A2 (pt)	2018-06-26	cenicriviroc para o tratamento da fibrose
DK3289080T3 (da)	2021-11-08	Genterapi til autosomalt dominante sygdomme
GB201509893D0 (en)	2015-07-22	Therapeutic agents
DK3262066T4 (da)	2023-08-21	Genterapi
ZA201600079B (en)	2017-09-27	Active mixtures
MA39483A (fr)	2015-09-24	Agents thérapeutiques cibles
GB201517263D0 (en)	2015-11-11	Therapeutic agents
EP3315131A4 (fr)	2019-02-27	Agent thérapeutique contre la fibrose
PL3318267T3 (pl)	2021-07-12	Środek leczniczy do leczenia zespołu huntera
GB201509885D0 (en)	2015-07-22	Therapeutic agents
DK3393478T3 (da)	2020-03-23	Kombinationsterapi
EP3308781A4 (fr)	2019-01-23	Agent hypotenseur
EP3362091A4 (fr)	2019-04-24	Polythérapie
EP3541931A4 (fr)	2020-11-04	Traitement combiné fractal
DE112016003293A5 (de)	2018-04-26	Feuerlöscher
GB201509888D0 (en)	2015-07-22	Therapeutic agents
DK3329004T3 (da)	2020-04-20	Terapeutiske oligonukleotider
EP3659609A4 (fr)	2021-04-21	Agent thérapeutique contre la fibrose
BR112017011897A2 (pt)	2018-07-03	métodos de tratamento da fibrose
GB201513299D0 (en)	2015-09-09	Therapeutic agents